Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
about
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsDiagnosis and subclassification of acute lymphoblastic leukemiaRedefining ALL classification: toward detecting high-risk ALL and implementing precision medicineCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaRecent advances and novel treatment paradigms in acute lymphocytic leukemiaChildhood acute lymphoblastic leukemia: Integrating genomics into therapyCD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaLNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitorsTreating adults with acute lymphocytic leukemia: new pharmacotherapy options.New Therapeutic Strategies in Acute Lymphocytic Leukemia.Safety evaluation of ruxolitinib for treating myelofibrosis.Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance.Childhood B-acute lymphoblastic leukemia: a genetic update.First do no harm: infectious deaths in pediatric ALL.Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.Biology of childhood acute lymphoblastic leukemia.The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical modelNovel agents for the treatment of childhood acute leukemia.Generation of human acute lymphoblastic leukemia xenografts for use in oncology drug discovery.Improving access to novel agents for childhood leukemia.Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)Molecular profiling of childhood cancer: Biomarkers and novel therapiesPOL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALLBiologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcomaTargeted drug discovery for pediatric leukemia.A 50-year journey to cure childhood acute lymphoblastic leukemiaGenetic loss of SH2B3 in acute lymphoblastic leukemia.Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.Genomic characterization of childhood acute lymphoblastic leukemia.Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.
P2860
Q26782539-180AE6F7-765B-4557-B71B-9BC13BEDBE91Q26824387-9C192070-A36B-43FD-878F-D2D47BECE019Q26864460-EA4E4915-E804-4467-BC91-E1815771DAEDQ27025242-E2C752AB-4F91-421B-B131-5422B7D2DF65Q28078076-2ED3C895-5E36-4A65-A3D6-35E3340D6ADFQ28080463-959CB71E-3BE2-4441-AD0F-3BF8745D5682Q28084879-3AF292CA-7924-4FBD-BF63-B5A86386D762Q28274115-83E691E1-BB06-4C1A-B0A1-970A1CB88382Q30243925-CE50D828-EE5C-46B1-9B83-91F8A524D9A4Q30252776-FF32AC48-1236-4C6E-9C8D-F6417D7A186FQ33415731-9E5A56FC-8012-4A8D-B0F4-BD9CA4B63810Q33578333-C1CEC281-C323-489C-8A21-F756670EB675Q33698398-0898AE35-6FFD-45B9-80B4-C72A350FD85BQ33711119-9E24F0BD-B839-423D-90B8-3346D5AA467CQ33755247-8BA251EF-A0A2-4B19-BC3B-FA2770AFE577Q33777616-D35E7CA0-D310-4885-BBB5-8C862E60D12BQ34047922-0D2E0346-1A7C-4827-A70B-1501478C4862Q34172033-C202E85F-F92D-4C9B-9230-4EE69A2F4A9FQ34314927-160D6F59-795C-436E-9B8B-17BFAE89849EQ34343785-3F310D5F-B19E-46E0-AE7D-E13D2B9D0694Q34605953-099A9648-CC7F-4DB7-8A89-313ADF8B5185Q34687627-EE2A8598-EBB9-4735-8D34-5E4457AAB2F1Q35079398-EF5D134C-97D4-4E1C-B25C-444715BF17A0Q35171267-8410769F-FD68-4FDD-A91D-7DF60F44A264Q35176311-FC099083-2F0A-40D0-8C18-8144CDEEC17BQ35192790-5CBC740D-76FC-4B62-8ED4-A0B34FC6C2EBQ35205279-A72837B0-0195-4C26-AA39-069E588FC01CQ35688742-CFCE7A94-460D-4E72-AA1C-AFF855E701B9Q35861111-6371A946-B521-41DB-B065-C50305CBEBFEQ35904943-7E9B6988-D86B-4231-B799-CFFB4831BBC4Q35987564-A46CA626-1C6F-4376-8A1D-9E21A9ECCF49Q36250783-80D85E0C-4A9B-45DE-B926-6316D514A3ABQ36544455-D8BF8FDB-266C-4927-91A8-4B4AC9F2872BQ36717196-F60EB3CB-1F33-4A67-91E2-03A87EDE6AD9Q36989223-29A7F5D0-DB8C-4F69-BF99-ABBCF4BF8823Q37166753-458A1AD1-A714-4F83-95CA-E6F192943B2CQ37215146-70D07806-9B82-4134-9443-8112531090CDQ37226741-5418BF53-0B9B-4DA7-A676-6EE799F80226Q37359118-018C83BA-7ADE-4B1C-AA8C-F1D50C185F12Q37429718-E86247D7-17F3-4B87-89C2-98C18F68707A
P2860
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Targeting JAK1/2 and mTOR in m ...... e acute lymphoblastic leukemia
@ast
Targeting JAK1/2 and mTOR in m ...... e acute lymphoblastic leukemia
@en
type
label
Targeting JAK1/2 and mTOR in m ...... e acute lymphoblastic leukemia
@ast
Targeting JAK1/2 and mTOR in m ...... e acute lymphoblastic leukemia
@en
prefLabel
Targeting JAK1/2 and mTOR in m ...... e acute lymphoblastic leukemia
@ast
Targeting JAK1/2 and mTOR in m ...... e acute lymphoblastic leukemia
@en
P2093
P2860
P50
P1433
P1476
Targeting JAK1/2 and mTOR in m ...... e acute lymphoblastic leukemia
@en
P2093
Alix E Seif
Cecilia Sheen
Cheryl L Willman
David M Barrett
David T Teachey
I-Ming Chen
J Racquel Collins
Jordan S Fridman
Junior W Hall
Kathryn G Roberts
P2860
P304
P356
10.1182/BLOOD-2012-03-415448
P407
P577
2012-09-06T00:00:00Z